Lowest Price Guaranteed From USD 4,899
Published
July 2020
Pages
280
View Count
22288
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Depression is one of the most common chronic neurological conditions in modern society. It is estimated that over 250 million people, across all age groups, suffer from some form of depression, worldwide. Moreover, this condition along with other mental health disorders are estimated to be responsible for productivity associated losses worth over USD 1 trillion, every year, at the global level. In fact, the US reported a sharp increase (~20%) in number of prescriptions for antidepressants and anti-anxiety drugs during the global lockdown enforced to curb the spread of COVID-19. According to the World Health Organization, the major roadblocks to effective treatment for depression and other mental illnesses include the lack of understanding of the aforementioned conditions resulting in an irrational social stigma, inaccurate diagnosis, and paucity of effective medication. In this context, it is worth highlighting that there is a growing body of clinical evidence supporting the therapeutic effect of psychedelic substances on psychiatric conditions, such as depressions. Experts in this field also believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications of the current pandemic.
Over time, it have been demonstrated that psychedelic substances interact with a variety of neurotransmitter pathways, including those of serotonin, acetylcholine, norepinephrine, and dopamine, among several others. In fact, there is evidence that an imbalance in the levels of serotonin in the brain, causes depression. Similarly, the aforementioned biomolecules have been associated with a plethora of neurological conditions. As a result, biocompatible molecules having the ability to modulate neurotransmitter production / function, have the potential to be put to therapeutic use. Early in the 21st Century, XYREM®, a gamma-hydroxybutyric acid based psychedelic drug was approved for the treatment of cataplexy in patients suffering from narcolepsy. In 2019, SPRAVATO® (an analogue of ketamine), developed by Johnson and Johnson, was approved for use in patients suffering from treatment-resistant depression. Recently, the US FDA granted the breakthrough drug designation to 3,4-Methylenedioxymethamphetamine (MDMA) and psilocybin, based on clinical evidence of these substances being capable of offering substantial therapeutic benefit in treating major depressive disorder, post-traumatic stress disorder and treatment resistant depression over other available therapies. Currently, several stakeholders in the pharmaceutical industry are actively evaluating the therapeutic potential of psychedelic substances against a wide array of mental health problems. As more players achieve proof-of-concept, this niche market is anticipated to witness substantial growth in the mid-long term.
The “Global Psychedelic Therapeutics Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of psychedelic therapeutics, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to estimate the existing market size and the future opportunity for psychedelic therapeutics, over the next decade. Based on multiple parameters, such as target patient population, likely adoption and the annual treatment cost, we have provided informed estimates on the evolution of psychedelic therapeutics market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] origin of substance (natural and synthetic) [B] type of psychedelic substance (gamma-hydroxybutyrate, Ketamine, MDMA, and psilocybin) [C] key geographical regions (North America, Europe, Asia Pacific and rest of the world) [D] target disease indications (depression and anxiety disorders, pain disorders, sleep related disorders and trauma) and [E] route of administration (oral, intravenous, intranasal and sublingual). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for psychedelic therapeutics, in the short-mid term and long term.
Chapter 3 provides a general overview of psychedelic therapeutics, including information on the role of psychedelic substances as an emerging treatment option and their historical evolution. The chapter lays emphasis on the different target therapeutic areas / affiliated symptoms that can be potentially treated with psychedelic therapeutics. It also includes a discussion on the regulations, toxicity concerns, and the various challenges regarding their medical use and future opportunities.
Chapter 4 includes information on more than 80 programs for psychedelic therapeutics that are either approved or being developed across different stages (commercial, clinical, and preclinical and discovery stage) for the treatment of various therapeutic areas. It features a comprehensive analysis of marketed / pipeline molecules, highlighting phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of psychedelic substance, origin of psychedelic substance, target therapeutic area (s), route of administration (intranasal, intravenous, oral, sublingual, topical, transdermal), dosing frequency (single dose, twice a week, once in two months and others). Additionally, the chapter includes information on drug developer(s), highlighting year of their establishment, company size, and location of headquarters.
Chapter 5 provides tabulated profiles of the companies that are engaged in the development of at least two or more psychedelics-based therapies (in phase II and above). Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
Chapter 6 provides a detailed analysis of completed, ongoing and planned clinical studies of various psychedelic therapeutics, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population and geographical distribution of trials, study design, leading industry (in terms of number of trials conducted), study focus, target therapeutic area, key geographical regions.
Chapter 7 provides an insightful analysis of clinical trial sites where the studies have been / are being conducted for evaluation of various psychedelic therapeutics, based on relevant parameters, such as type of psychedelic substance, trial phase, target disease indications and location of the trial.
Chapter 8 provides an analysis of KOLs in the field of psychedelic therapeutics. It features a comprehensive list of principal investigators of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on parameters, such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on LinkedIn).
Chapter 9 provides an analysis of nearly 550 grants that were awarded to research institutes engaged in psychedelic therapeutics related projects, in the period between 2016 and 2020 (till April) based on the important parameters associated with grants, such as the year of grant award, amount awarded, funding institute centre, support period, type of grant application, purpose of grant award, activity code, responsible study section, prominent program officers, and type of recipient organizations.
Chapter 10 features a discussion of the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2017. It includes a brief description of various types of partnership models (namely acquisitions and mergers, licensing agreements, product development agreements, research agreements, research and development agreement, clinical trial agreements, joint venture agreements and other agreements) that have been adopted by stakeholders in this domain. In addition, it includes a detailed analysis of partnerships, based on year of partnership, type of partnership, and regional activity.
Chapter 11 features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2017-2020, based on parameters, such as key value drivers, year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.
Chapter 12 features a detailed market forecast analysis, highlighting the likely growth of psychedelic therapeutics till the year 2030. We have provided inputs on likely distribution of the current and forecasted opportunity across origin of substance (natural and synthetic), type of psychedelic substance (gamma-hydroxybutyrate, Ketamine, MDMA, and psilocybin), key geographical regions (North America, Europe, Asia Pacific and rest of the world), target disease indications (depression and anxiety disorders, pain disorders, sleep related disorders and trauma) and route of administration (oral, intravenous, intranasal and sublingual). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 13 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights the evolutionary trends that were identified during the course of the study and are expected to influence the future of the psychedelic therapeutics market.
Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Andrew Chadeayne (Founder & Chief Executive Officer, CaaMTech), Janakan Krishnarajah (Chief Operating Officer and Chief Medical Officer, iX Biopharma), Alexander Speiser (Chief Operating Officer, Orthogonal Thinker), Tracy Cheung (Chief Communications Officer, COMPASS Pathways), Benjamin Kelmendi (Yale University).
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. History of Psychedelic Substances
3.3. Potential Therapeutic Applications of Psychedelic Substances
3.4. Regulation, Toxicity Concerns, Procurement-related Challenges and Perceptions Regarding Medical Use
3.5. Future Opportunities
4. MARKET LANDSCAPE: PSYCHEDELIC THERAPEUTICS
4.1. Chapter Overview
4.2. Psychedelic Therapeutics: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Psychedelic Substance
4.2.3. Analysis by Origin of Psychedelic Substance
4.2.4. Analysis by Target Therapeutic Area
4.2.5. Analysis by Route of Administration
4.2.6. Analysis by Dosing Frequency
4.3. Psychedelic Therapeutics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4. 3.3. Analysis by Location of Headquarters
4.4. Grid Analysis: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Celon Pharma
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Psychedelic Therapeutics Portfolio
5.2.3.1. Esketamine DPI
5.2.4. Recent Developments and Future Outlook
5.3. iX Biopharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Psychedelic Therapeutics Portfolio
5.3.3.1. Wafermine™
5.3.3.2. Unnamed (Ketamine)
5.3.4. Recent Developments and Future Outlook
5.4. MAPS Public Benefit
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Psychedelic Therapeutics Portfolio
5.4.3.1. Unnamed (MDMA)
5.4.3.2. Unnamed (Ibogaine Hydrochloride)
5.4.3.3. Unnamed (LSD)
5.4.3.4. Unnamed (Ayahuasca)
5.4.4. Recent Developments and Future Outlook
5.5. MindMed
5.5.1. Company Overview
5.5.2. Psychedelic Therapeutics Portfolio
5.5.2.1. LSD Micro-dosing
5.5.2.2. 18-MC
5.5.2.3. Unnamed (LSD and MDMA)
5.5.3. Recent Developments and Future Outlook
5.6. Janssen Pharmaceuticals
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Psychedelic Therapeutics Portfolio
5.6.3.1. SPRAVATO®
5.6.4. Recent Developments and Future Outlook
5.7. Jazz Pharmaceutical
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Psychedelic Therapeutics Portfolio
5.7.3.1. XYREM®
5.7.3.2. JZP-258
5.7.3.3. JZP-324
5.7.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Psychedelic Therapeutics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase
6.3.3. Analysis by Trial Recruitment Status
6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.5. Analysis by Study Design
6.3.6. Leading Trial Sponsors: Analysis by Number of Registered Trials
6.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
6.3.8. Word Cloud: Key Focus Areas
6.3.9. Analysis by Target Therapeutic Area
6.3.10. Popular Interventions: Analysis by Number of Registered Trials
6.3.11. Geographical Analysis by Number of Registered Trials
6.3.12. Geographical Analysis by Trial Recruitment Status
6.3.13. Geographical Analysis by Number of Patients Enrolled
7. CLINICAL TRIAL SITE ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Psychedelic Therapeutics: Clinical Trial Site Analysis
7.3.1. Analysis by Type of Psychedelic Substance
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Target Therapeutic Area
7.3.4. Analysis by Location of Clinical Trial Site
8. KEY OPINION LEADER (KOL) ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs
8.4. Prominent KOLs
8.5. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Emory School of Medicine)
8.6.2. KOL Profile: B (Imperial College London)
8.6.3. KOL Profile: C (Rigshospitalet)
8.6.4. KOL Profile: D (Thriving Mind South Florida)
8.6.5. KOL Profile: E (University Health Network)
9. ACADEMIC GRANTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Psychedelic Therapeutics: Analysis of Academic Grants
9.3.1. Analysis by Year of Grant Award
9.3.2. Analysis by Amount Awarded
9.3.3. Analysis by Funding Institute Center
9.3.4. Analysis by Support Period
9.3.5. Analysis by Funding Institute Center and Support Period
9.3.6. Analysis by Type of Grant Application
9.3.7. Analysis by Purpose of Grant Award
9.3.8. Analysis by Activity Code
9.3.9. Analysis by Study Section Involved
9.3.10. Analysis by Recipient Organization
9.3.11. Geographical Distribution of Recipient Organizations
9.3.12. Word Cloud: Emerging Focus Areas
9.3.13. Popular Psychedelic Therapeutics: Analysis by Number of Grants
9.3.14. Popular Funding Institute Centers: Analysis by Number of Grants
9.3.15. Prominent Program Officers: Analysis by Number of Grants
9.3.16. Popular Recipient Organizations: Analysis by Number of Grants
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Psychedelic Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partnership and Type of Psychedelic Substance Involved
10.3.4. Analysis by Type of Partnership and Phase of Development of Involved Intervention
10.3.5. Analysis by Type of Partnership and Target Therapeutic Area Mentioned
10.3.6. Analysis by Type of Psychedelic Substance and Target Therapeutic Area
10.3.7. Analysis by Type of Partnership and Type of Partner
10.3.8. Analysis by Type of Psychedelic Substance Involved and Type of Partner
10.3.9. Most Active Players: Analysis by Number of Partnerships
10.3.10. Regional Analysis
10.3.10.1 Intercontinental and Intracontinental Agreements
11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Acquisition Models
11.3. Psychedelic Therapeutics: Mergers and Acquisitions
11.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
11.3.2. Analysis by Type of Acquisition
11.3.3. Analysis by Type of Psychedelic Substance Involved
11.3.4. Analysis by Year of Acquisition and Type of Psychedelic Substance Involved
11.3.5. Most Active Players: Analysis by Number of Acquisitions
11.3.6. Regional Analysis
11.3.6.1. Continent-Wise Distribution of Acquisitions
11.3.6.2. Country-Wise Distribution of Acquisitions
11.3.7. Analysis by Key Value Drivers
11.3.7.1, Analysis by Year of Acquisition and Key Value Drivers
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Assumptions
12.3. Global Psychedelic Therapeutics Market, 2020-2030
12.4. Global Psychedelic Therapeutics Market: Individual Product Sales Forecasts
12.4.1. COMP360 (COMPASS Pathways)
12.4.1.1. Target Patient Population
12.4.1.2. Sales Forecast
12.4.2. Esketamine DPI (Celon Pharma)
12.4.2.1. Target Patient Population
12.4.2.2. Sales Forecast
12.4.3. FT218 (Avadel Pharmaceuticals)
12.4.3.1. Target Patient Population
12.4.3.2. Sales Forecast
12.4.4. JZP-258 (Jazz Pharmaceuticals)
12.4.4.1. Target Patient Population
12.4.4.2. Sales Forecast
12.4.5. NRX-100 (NeuroRx)
12.4.5.1. Target Patient Population
12.4.5.2. Sales Forecast
12.4.6. R-107 (Doughlas pharmaceuticals)
12.4.6.1. Target Patient Population
12.4.6.2. Sales Forecast
12.4.7. SPRAVATO® (Janssen Pharmaceuticals)
12.4.7.1. Target Patient Population
12.4.7.2. Sales Forecast
12.4.8. Unnamed (MDMA) (MAPS Public Benefit)
12.4.8.1. Target Patient Population
12.4.8.2. Sales Forecast
12.4.9. Unnamed (Psilocybin) (The Emmes Company)
12.4.9.1. Target Patient Population
12.4.9.2. Sales Forecast
12.4.10. Wafermine™ (iX Biopharma)
12.4.10.1. Target Patient Population
12.4.10.2. Sales Forecast
12.4.11. XYREM® (Jazz Pharmaceuticals)
12.4.11.1. Target Patient Population
12.4.11.2. Sales Forecast
12.5. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substance, 2020-2030
12.5.1. Global Psychedelic Therapeutics Market for Synthetic Substances, 2020-2030
12.5.2. Global Psychedelic Therapeutics Market for Natural Substances, 2020-2030
12.6. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, 2020-2030
12.6.1. Global Psychedelic Therapeutics Market for GHB, 2020-2030
12.6.2. Global Psychedelic Therapeutics Market for Ketamine, 2020-2030
12.6.3. Global Psychedelic Therapeutics Market for MDMA, 2020-2030
12.6.4. Global Psychedelic Therapeutics Market for Psilocybin, 2020-2030
12.7. Global Psychedelic Therapeutics Market: Distribution by Geography, 2020-2030
12.7.1. Psychedelic Therapeutics Market in North America, 2020-2030
12.7.2. Psychedelic Therapeutics Market in Europe, 2020-2030
12.7.3. Psychedelic Therapeutics Market in Asia-Pacific and Rest of the World, 2020-2030
12.8. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030
12.8.1. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, 2020-2030
12.8.2. Global Psychedelic Therapeutics Market for Pain Disorders, 2020-2030
12.8.3. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, 2020-2030
12.8.4. Global Psychedelic Therapeutics Market for Trauma, 2020-2030
12.9. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, 2020-2030
12.9.1. Global Psychedelic Therapeutics Market for Intranasal Therapies, 2020-2030
12.9.2. Global Psychedelic Therapeutics Market for Intravenous Therapies, 2020-2030
12.9.3. Global Psychedelic Therapeutics Market for Oral Therapies, 2020-2030
12.9.4. Global Psychedelic Therapeutics Market for Sublingual Therapies, 2020-2030
13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2 CaaMTech
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Andrew Chadeayne, Founder & Chief Executive Officer
14.3. MindMed
14.3.1. Company Snapshot
14.3.2. Interview Transcript: JR Rahn, Founder & Chief Executive Officer
14.4. iX Biopharma
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer
14.5 Orthogonal Thinkers
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Tracy Cheung, Alexander Speiser, Chief Operating Officer
14.6 COMPASS Pathways
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Tracy Cheung, Chief Communications Officer
14.7 Yale University
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Benjamin Kelmendi, Assistant Professor of Psychiatry
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1. Historical Evolution of Psychedelics
Figure 3.2. Psychedelic Substances: Potential Therapeutic Areas
Figure 3.3. Classification of Psychedelic Substances under the Federal Controlled Substances Act
Figure 3.4. Psychedelic Therapeutics: Status of Legalization / Decriminalization Across Different Geographies
Figure 3.5. Psychedelic Therapeutics: Toxicity Comparison of Different Substances
Figure 4.1. Psychedelic Therapeutics: Distribution by Phase of Development
Figure 4.2. Psychedelic Therapeutics: Distribution by Type of Psychedelic Substance
Figure 4.3. Psychedelic Therapeutics: Distribution by Origin of Psychedelic Substance
Figure 4.4. Psychedelic Therapeutics: Distribution by Target Therapeutic Area
Figure 4.5. Psychedelic Therapeutics: Distribution by Route of Administration
Figure 4.6. Psychedelic Therapeutics: Distribution by Dosing Frequency
Figure 4.7. Psychedelic Therapeutics Developers: Distribution by Year of Establishment
Figure 4.8. Psychedelic Therapeutics Developers: Distribution by Company Size
Figure 4.9. Psychedelic Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.10. Grid Representation: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters
Figure 5.1. Celon Pharma: Annual Revenues, 2016- 2019 (PLN Million)
Figure 5.2. iX Biopharma: Annual Revenues, 2015- 2019 (USD Million)
Figure 5.3. MAPS Public Benefit: Annual Revenues, 2016- Q1 2020 (USD Million)
Figure 5.4. Janssen Pharmaceuticals: Annual Revenues, 2016- Q1 2020 (USD Million)
Figure 5.5. Jazz Pharmaceutical: Annual Revenues, 2015- Q1 2020 (USD Million)
Figure 6.1. Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Figure 6.2. Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.4. Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Figure 6.5. Clinical Trial Analysis: Distribution by Study Design
Figure 6.6. Leading Trial Sponsors: Distribution by Number of Registered Trials
Figure 6.7. Leading Industry Sponsors: Distribution by Number of Registered Trials
Figure 6.8. Word Cloud: Key Focus Areas
Figure 6.9. Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 6.10. Popular Interventions: Distribution by Number of Registered Trials
Figure 6.11. Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.12. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Figure 6.13. Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 7.1. Clinical Trial Site Analysis: Cumulative Distribution of Clinical Trial Centre
Figure 7.2. Clinical Trial Site Analysis: Distribution by Type of Psychedelic Substance
Figure 7.3. Clinical Trial Site Analysis: Distribution by Trial Phase
Figure 7.4. Clinical Trial Site Analysis: Distribution by Target Therapeutic Area
Figure 7.5. Clinical Trial Site Analysis: Distribution by Location of Clinical Trial Center
Figure 8.1. KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Figure 8.2. KOL Analysis: Geographical Distribution of KOLs in America
Figure 8.3. KOL Analysis: Geographical Distribution of KOLs in Europe, Asia-Pacific and RoW
Figure 8.4. KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
Figure 8.5. KOL Analysis: Leading Organizations (KOL Affiliation)
Figure 8.6. KOL Analysis: Dot-Plot of KOLs
Figure 8.7. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Figure 8.8. KOL Analysis: Most Prominent KOLs
Figure 9.1. Grant Analysis: Cumulative Trend by Year of Grant Award, 2015-2020
Figure 9.2. Grant Analysis: Cumulative Distribution by Amount Awarded, 2015-2020 (USD Million)
Figure 9.3. Grant Analysis: Distribution by Funding Institute Center
Figure 9.4. Grant Analysis: Distribution by Support Period
Figure 9.5. Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 9.6. Grant Analysis: Distribution by Type of Grant Application
Figure 9.7. Grant Analysis: Distribution by Purpose of Grant Award
Figure 9.8. Grant Analysis: Distribution by Activity Code
Figure 9.9. Grant Analysis: Distribution by Study Section Involved
Figure 9.10. Grant Analysis: Distribution by Recipient Organization
Figure 9.11. Grant Analysis: Regional Distribution of Recipient Organizations
Figure 9.12. Word Cloud Analysis: Emerging Focus Areas
Figure 9.13. Popular Psychedelic Therapeutics: Distribution by Number of Grants
Figure 9.14. Popular Funding Institute Centers: Distribution by Number of Grants
Figure 9.15. Grant Analysis: Prominent Program Officers
Figure 9.16. Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Psychedelic Substance Involved
Figure 10.4. Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development of Involved Intervention
Figure 10.5. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance and Target Therapeutic Area
Figure 10.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.7. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance Involved and Type of Partner
Figure 10.8. Most Active Players: Distribution by Number of Partnerships
Figure 10.9. Partnership and Collaborations: Regional Distribution
Figure 10.10. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 11.1. Mergers and Acquisitions: Cumulative Year-wise Trend, 2017-2020
Figure 11.2. Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 11.3. Mergers and Acquisitions: Distribution by Type of Psychedelic Substance Involved
Figure 11.4. Mergers and Acquisitions: Distribution by Year of Acquisition and Type of Psychedelic Substance Involved
Figure 11.5. Most Active Players: Distribution by Number of Acquisition
Figure 11.6. Mergers and Acquisitions: Regional Distribution
Figure 11.7. Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 11.8. Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 11.9. Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 12.1. Global Psychedelic Therapeutics Market, 2020-2030 (USD Million)
Figure 12.2. COMP360 (COMPASS Pathways): Target Patient Population
Figure 12.3. COMP360 (COMPASS Pathways): Sales Forecast
Figure 12.4. Esketamine DPI (Celon Pharma): Target Patient Population
Figure 12.5. Esketamine DPI (Celon Pharma): Sales Forecast
Figure 12.6. FT218 (Avadel Pharmaceuticals): Target Patient Population
Figure 12.7. FT218 (Avadel Pharmaceuticals): Sales Forecast
Figure 12.8. JZP-258 (Jazz Pharmaceuticals): Target Patient Population
Figure 12.9. JZP-258 (Jazz Pharmaceuticals): Sales Forecast
Figure 12.10. NRX-100 (NeuroRx): Target Patient Population
Figure 12.11. NRX-100 (NeuroRx): Sales Forecast
Figure 12.12. R-107 (Doughlas pharmaceuticals): Target Patient Population
Figure 12.13. R-107 (Doughlas pharmaceuticals): Sales Forecast
Figure 12.14. SPRAVATO® (Janssen Pharmaceuticals): Target Patient Population
Figure 12.15. SPRAVATO® (Janssen Pharmaceuticals): Sales Forecast
Figure 12.16. Unnamed (MDMA) (MAPS Public Benefit): Target Patient Population
Figure 12.17. Unnamed (MDMA) (MAPS Public Benefit): Sales Forecast
Figure 12.18. Unnamed (Psilocybin) (The Emmes Company): Target Patient Population
Figure 12.19. Unnamed (Psilocybin) (The Emmes Company): Sales Forecast
Figure 12.20. Wafermine™ (iX Biopharma): Target Patient Population
Figure 12.21. Wafermine™ (iX Biopharma): Sales Forecast
Figure 12.22. XYREM® (Jazz Pharmaceuticals): Target Patient Population
Figure 12.23. XYREM® (Jazz Pharmaceuticals): Sales Forecast
Figure 12.24. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substances, 2020-2030 (USD Million)
Figure 12.25. Global Psychedelic Therapeutics Market for Synthetic Substances, 2020-2030
Figure 12.26. Global Psychedelic Therapeutics Market for Natural Substances, 2020-2030
Figure 12.27. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, 2020-2030 (USD Million)
Figure 12.28. Global Psychedelic Therapeutics Market for GHB, 2020-2030
Figure 12.29. Global Psychedelic Therapeutics Market for Ketamine, 2020-2030
Figure 12.30. Global Psychedelic Therapeutics Market for MDMA, 2020-2030
Figure 12.31. Global Psychedelic Therapeutics Market for Psilocybin, 2020-2030
Figure 12.32. Global Psychedelic Therapeutics Market: Distribution by Geography, 2020-2030 (USD Million)
Figure 12.33. Global Psychedelic Therapeutics Market in North America, 2020-2030 (USD Million)
Figure 12.34. Global Psychedelic Therapeutics Market in Europe, 2020-2030 (USD Million)
Figure 12.35. Global Psychedelic Therapeutics Market in Asia Pacific and Rest of the World, 2020-2030 (USD Million)
Figure 12.36. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Figure 12.37. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, 2020-2030 (USD Million)
Figure 12.38. Global Psychedelic Therapeutics Market for Pain Disorders, 2020-2030 (USD Million)
Figure 12.39. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, 2020-2030 (USD Million)
Figure 12.40. Global Psychedelic Therapeutics Market for Trauma, 2020-2030 (USD Million)
Figure 12.41. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 12.42. Global Psychedelic Therapeutics Market for Intranasal Therapies, 2020-2030 (USD Million)
Figure 12.43. Global Psychedelic Therapeutics Market for Intravenous Therapies, 2020-2030 (USD Million)
Figure 12.44. Global Psychedelic Therapeutics Market for Oral Therapies, 2020-2030 (USD Million)
Figure 12.45. Global Psychedelic Therapeutics Market for Sublingual Therapies, 2020-2030 (USD Million)
Table 4.1. Psychedelic Therapeutics: Marketed and Development Pipeline
Table 4.2. Psychedelic Therapeutics: List of Developers
Table 5.1. Psychedelic Therapeutics: List of Companies Profiled
Table 5.2. Celon Pharma: Company Snapshot
Table 5.3. Drug Profile: Esketamine DPI
Table 5.4. Celon Pharma: Recent Developments and Future Outlook
Table 5.5. iX Biopharma: Company Snapshot
Table 5.6. Drug Profile: Wafermine®
Table 5.7. Drug Profile: Unnamed (Ketamine)
Table 5.8. iX Biopharm: Recent Developments and Future Outlook
Table 5.9. MAPS Public Benefit: Company Snapshot
Table 5.10. Drug Profile: Unnamed (MDMA)
Table 5.11. Drug Profile: Unnamed Ibogaine Hydrochloride
Table 5.12. Drug Profile: Unnamed (LSD)
Table 5.13. Drug Profile: Unnamed (Ayahuasca)
Table 5.14. MAPS Public Benefit: Recent Developments and Future Outlook
Table 5.15. MindMed: Company Snapshot
Table 5.16. Drug Profile: LSD Micro-Dosing
Table 5.17. Drug Profile: 18-MC
Table 5.18. MindMed: Recent Developments and Future Outlook
Table 5.19. Janssen Pharmaceutical: Company Snapshot
Table 5.20. Drug Profile: SPRAVATO®
Table 5.21. Janssen Pharmaceutical: Recent Developments and Future Outlook
Table 5.22. Jazz Pharmaceutical: Company Snapshot
Table 5.23. Drug Profile: XYREM®
Table 5.24. Drug Profile: JZP-258
Table 5.25. Drug Profile: JZP-324
Table 5.26. Jazz pharmaceutical: Recent Developments and Future Outlook
Table 7.1. Psychedelic Therapeutics: List of Principal Investigators
Table 7.2. KOLs: Roots Analysis Proprietary Scoring System
Table 7.3. KOL Profile: A (Emory School of Medicine)
Table 7.4. KOL Profile: B (Imperial College London)
Table 7.5. KOL Profile: C (Rigshospitalet)
Table 7.6. KOL Profile: D (Thriving Mind South Florida)
Table 7.7. KOL Profile: E (University Health Network)
Table 10.1. Psychedelic Therapeutics: List of Partnerships and Collaborations
Table 11.1. Psychedelic Therapeutics: List of Mergers and Acquisition
Table 11.2. Psychedelic Therapeutics: Key Growth Drivers
Table.15.1. Psychedelic Therapeutics: Distribution by Phase of Development
Table.15.2. Psychedelic Therapeutics: Distribution by Type of Psychedelic Substance
Table.15.3. Psychedelic Therapeutics: Distribution by Origin of Psychedelic Substance
Table.15.4. Psychedelic Therapeutics: Distribution by Target Therapeutic Area
Table.15.5. Psychedelic Therapeutics: Distribution by Route of Administration
Table.15.6. Psychedelic Therapeutics: Distribution by Dosing Frequency
Table.15.7. Psychedelic Therapeutics Developers: Distribution by Year of Establishment
Table.15.8. Psychedelic Therapeutics Developers: Distribution by Company Size
Table.15.9. Celon Pharma: Annual Revenues, 2016- 2019 (PLN Million)
Table.15.10. iX Biopharma: Annual Revenues, 2015- 2019 (USD Million)
Table.15.11. MAPS Public Benefit: Annual Revenues, 2016- Q1 2020 (USD Million)
Table.15.12. Janssen Pharmaceuticals: Annual Revenues, 2016- Q1 2020 (USD Million)
Table.15.13. Jazz Pharmaceutical: Annual Revenues, 2015- Q1 2020 (USD Million)
Table.15.14. Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Table.15.15. Clinical Trial Analysis: Distribution by Trial Phase
Table.15.16. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table.15.17. Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Table.15.18. Clinical Trial Analysis: Distribution by Study Design
Table.15.19. Leading Trial Sponsors: Distribution by Number of Registered Trials
Table.15.20. Leading Industry Sponsors: Distribution by Number of Registered Trials
Table.15.21. Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table.15.22. Popular Interventions: Distribution by Number of Registered Trials
Table.15.23. Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table.15.24. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table.15.25. Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table.15.26. Clinical Trial Site Analysis: Cumulative Distribution of Clinical Trial Centre
Table.15.27. Clinical Trial Site Analysis: Distribution by Type of Psychedelic Substance
Table.15.28. Clinical Trial Site Analysis: Distribution by Trial Phase
Table.15.29. Clinical Trial Site Analysis: Distribution by Target Therapeutic Area
Table.15.30. Clinical Trial Site Analysis: Distribution by Location of Clinical Trial Center
Table.15.31. KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Table.15.32. KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
Table.15.33. KOL Analysis: Leading Organizations (KOL Affiliation)
Table.15.34. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Table.15.35. KOL Analysis: Most Prominent KOLs
Table.15.36. Grant Analysis: Cumulative Trend by Year of Grant Award, 2015-2020
Table.15.37. Grant Analysis: Cumulative Distribution by Amount Awarded, 2015-2020 (USD Million)
Table.15.38. Grant Analysis: Distribution by Funding Institute Center
Table.15.39. Grant Analysis: Distribution by Support Period
Table.15.40. Grant Analysis: Distribution by Funding Institute Center and Support Period
Table.15.41. Grant Analysis: Distribution by Type of Grant Application
Table.15.42. Grant Analysis: Distribution by Purpose of Grant Award
Table.15.43. Grant Analysis: Distribution by Activity Code
Table.15.44. Grant Analysis: Distribution by Study Section Involved
Table.15.45. Grant Analysis: Distribution by Recipient Organization
Table.15.46. Word Cloud Analysis: Emerging Focus Areas
Table.15.47. Popular Psychedelic Therapeutics: Distribution by Number of Grants
Table.15.48. Popular Funding Institute Centers: Distribution by Number of Grants
Table.15.49. Grant Analysis: Prominent Program Officers
Table.15.50. Popular Recipient Organizations: Distribution by Number of Grants
Table.15.51. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2020
Table.15.52. Partnerships and Collaborations: Distribution by Type of Partnership
Table.15.53. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Psychedelic Substance Involved
Table.15.54. Partnerships and Collaborations: Distribution by Type of Partnership and Phase of Development of Involved Intervention
Table.15.55. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance and Target Therapeutic Area
Table.15.56. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table.15.57. Partnerships and Collaborations: Distribution by Type of Psychedelic Substance Involved and Type of Partner
Table.15.58. Most Active Players: Distribution by Number of Partnerships
Table.15.59. Partnership and Collaborations: Regional Distribution
Table.15.60. Mergers and Acquisitions: Cumulative Year-wise Trend, 2017-2020
Table.15.61. Mergers and Acquisitions: Distribution by Type of Acquisition
Table.15.62. Mergers and Acquisitions: Distribution by Type of Psychedelic Substance Involved
Table.15.63. Mergers and Acquisitions: Distribution by Year of Acquisition and Type of Psychedelic Substance Involved
Table.15.64. Most Active Players: Distribution by Number of Acquisition
Table.15.65. Mergers and Acquisitions: Regional Distribution
Table.15.66. Mergers and Acquisitions: Distribution by Key Value Drivers
Table.15.67. Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table.15.68. Global Psychedelic Therapeutics Market, 2020-2030 (USD Million)
Table.15.69. COMP360 (COMPASS Pathways): Sales Forecast
Table.15.70. Esketamine DPI (Celon Pharma): Sales Forecast
Table.15.71. FT218 (Avadel Pharmaceuticals): Sales Forecast
Table.15.72. JZP-258 (Jazz Pharmaceuticals): Sales Forecast
Table.15.73. NRX-100 (NeuroRx): Sales Forecast
Table.15.74. R-107 (Doughlas pharmaceuticals): Sales Forecast
Table.15.75. SPRAVATO® (Janssen Pharmaceuticals): Sales Forecast
Table.15.76. Unnamed (MDMA) (MAPS Public Benefit): Sales Forecast
Table.15.77. Unnamed (Psilocybin) (The Emmes Company): Sales Forecast
Table.15.78. Wafermine™ (iX Biopharma): Sales Forecast
Table.15.79. XYREM® (Jazz Pharmaceuticals): Sales Forecast
Table.15.80. Global Psychedelic Therapeutics Market: Distribution by Origin of Psychedelic Substances, 2020-2030 (USD Million)
Table.15.81. Global Psychedelic Therapeutics Market for Synthetic Substances, 2020-2030 (USD Million)
Table.15.82. Global Psychedelic Therapeutics Market for Natural Substances, 2020-2030 (USD Million)
Table.15.83. Global Psychedelic Therapeutics Market: Distribution by Type of Psychedelic Substance, 2020-2030 (USD Million)
Table.15.84. Global Psychedelic Therapeutics Market for GHB, 2020-2030 (USD Million)
Table.15.85. Global Psychedelic Therapeutics Market for Ketamine, 2020-2030 (USD Million)
Table.15.86. Global Psychedelic Therapeutics Market for MDMA, 2020-2030 (USD Million)
Table.15.87. Global Psychedelic Therapeutics Market for Psilocybin, 2020-2030 (USD Million)
Table.15.88. Global Psychedelic Therapeutics Market: Distribution by Geography, 2020-2030 (USD Million)
Table.15.89. Global Psychedelic Therapeutics Market in North America, 2020-2030 (USD Million)
Table.15.90. Global Psychedelic Therapeutics Market in Europe, 2020-2030 (USD Million)
Table.15.91. Global Psychedelic Therapeutics Market in Asia Pacific and Rest of the World, 2020-2030 (USD Million)
Table.15.92. Psychedelic Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Table.15.93. Global Psychedelic Therapeutics Market for Depression and Anxiety Disorders, 2020-2030 (USD Million)
Table.15.94. Global Psychedelic Therapeutics Market for Pain Disorders, 2020-2030 (USD Million)
Table.15.95. Global Psychedelic Therapeutics Market for Sleep-Related Disorders, 2020-2030 (USD Million)
Table.15.96. Global Psychedelic Therapeutics Market for Trauma, 2020-2030 (USD Million)
Table.15.97. Global Psychedelic Therapeutics Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Table.15.98. Global Psychedelic Therapeutics Market for Intranasal Therapies, 2020-2030 (USD Million)
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES